Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPUR® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist. The results were presented in a poster at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Atlanta, October 17-21, 2009.
MENOPUR® vs. rFSH in GnRH Antagonist Cycles Interim Study Analysis
In an interim analysis of a multicenter, randomized, open-label exploratory study of IVF cycles using a GnRH antagonist, patients were randomized prior to stimulation with either MENOPUR® or recombinant follicle stimulating hormone (rFSH), and luteal support with either ENDOMETRIN® (progesterone) Vaginal Insert 100 mg or progesterone-in-oil (PIO). The overall continuing pregnancy rate was 43.1 percent>
"We are very encouraged by these interim results," said Ed Trott, vice president, medical affairs. "We anticipate that the final results of the study will add to the growing body of evidence suggesting that hMG offers better embryo quality and higher implantation and live birth rates when compared to using rFSH alone."
Maternal morbidity and pregnancy risks higher for gestational carriers